GHRS

GH Research PLC

19.56

Nov 10 • 3:59 PM ET +0.30 (1.56%)

19.56

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology Ireland Small NASD

Peers: DFTX CMPS AXSM PBM ACAD NMRA CMND SUPN JNJ NBIX

| Held by: IBB PSIL EIRL BBC IBBQ BIB FPXE

Scroll to Statements

Index	-
Market Cap	1.34B
Enterprise Value	980.35M
Income	-62.27M
Sales	0.00M
Book/sh	5.24
Cash/sh	5.28
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	73
IPO	Jun 25, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.73
P/C	3.70
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	28.70
Current Ratio	28.70
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.99
EPS next Y	-1.83
EPS next Q	-0.31
EPS this Y	-51.26%
EPS next Y	-53.19%
EPS next 5Y	-
EPS past 3/5Y	-22.35% -162.03%
Sales past 3/5Y	- -
EPS Y/Y TTM	-33.76%
Sales Y/Y TTM	-
EPS Q/Q	-52.04%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	24.34% -

Insider Own	25.83%
Insider Trans	0.00%
Inst Own	70.10%
Inst Trans	10.59%
ROA	-18.16%
ROE	-18.79%
ROIC	-17.32%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.01%
SMA50	-14.32%
SMA200	-9.65%
Trades

Shs Outstand	68.64M
Shs Float	50.91M
Short Float	4.08%
Short Ratio	6.92
Short Interest	2.08M
52W High	31.44 -37.78%
52W Low	12.04 62.46%
Volatility	7.57% 6.42%
ATR (14)	1.25
RSI (14)	43.93
Beta	1.33
Rel Volume	0.36
Avg Volume	300.34K
Volume	108,761

Perf Week	-3.55%
Perf Month	-2.30%
Perf Quarter	-35.32%
Perf Half Y	-9.19%
Perf YTD	54.02%
Perf Year	44.46%
Perf 3Y	138.25%
Perf 5Y	-20.00%
Perf 10Y	-
Recom	1.00
Target Price	41.70
Prev Close	19.26
Price	19.56
Change %	1.56%

Consensus

Strong Buy

Avg. Price Target

$41.70

Implied Upside

+113.2%

Analysts7incl. previous ratings

Rating Distribution7 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 27, 2026	Initiated	WWells Fargo	Overweight	$44	+124.9%
Oct 13, 2025	Initiated	NNeedham	Buy	$19	-2.9%
Jun 04, 2025	Resumed	CCantor Fitzgerald	Overweight	$25	+27.8%
Mar 13, 2025	Initiated	GGuggenheim	Buy	$32	+63.6%
Mar 07, 2025	Initiated	RRBC Capital Mkts	Outperform	$31	+58.5%
Feb 13, 2025	Initiated	CCantor Fitzgerald	Overweight	$14	-28.4%
Aug 16, 2022	Initiated	HH.C. Wainwright	Buy	$45	+130.1%
Jun 16, 2022	Initiated	RROTH Capital	Buy	$66	+237.4%

Aug-06-26 07:00AM	GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +5.18%
Jul-27-26 10:38AM	CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners (Stocktwits)
Jul-21-26 09:00AM	A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening (PR Newswire)
Jul-17-26 08:50AM	Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time (PR Newswire)
Jul-16-26 07:44AM	Why Psychedelic stocks are surging today (Investing.com) +8.21%
06:33AM	Loading…
06:33AM	GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS) (InvestorsHub)
Jul-14-26 03:00PM	The Race to Commercialize the Worlds Most Powerful Psychedelic (WSJ) +5.60%
Jul-13-26 02:59PM	Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says (Proactive)
Jun-26-26 09:30AM	A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year (PR Newswire) +11.37%
Jun-04-26 07:00AM	GH Research Announces Publication of Phase 2a Postpartum Depression Results (GlobeNewswire)
May-18-26 10:03AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
May-14-26 07:00AM	GH Research Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-26 08:00AM	GH Research Announces Pricing of $117.5 Million Underwritten Offering (GlobeNewswire)
Apr-24-26 03:59PM	FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit. (Barrons.com) +7.66%
Apr-22-26 08:49AM	Can I have some, please?: Trump jokes as he signs psychedelics order after Joe Rogan push. These stocks soar (Moneywise) -8.23%
02:34PM	Loading…
Apr-20-26 02:34PM	Market Feels Weak, But Stocks Tell Stories (GuruFocus.com) +17.23%
12:41PM	Trump Signs Psychedelic Drugs Order. 4 Stocks That Are Surging. (Barrons.com)
11:48AM	Trump Pushes for Speedy Psychedelic Approvals, Sending Stocks Surging (The Wall Street Journal)
09:00AM	GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness (GlobeNewswire)
08:26AM	Psychedelic stocks rally with Trump's support (MarketWatch)
08:18AM	Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring. (Barrons.com)
05:53AM	Psychedelic stocks soar after Trump signs executive order to fast-track treatments (Investing.com)
Mar-25-26 11:10AM	GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD (GlobeNewswire)
Mar-09-26 10:50AM	CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions (PR Newswire)
Mar-08-26 11:17AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks) +5.01%
Mar-05-26 07:00AM	GH Research Reports Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire) -5.13%
Feb-27-26 11:44AM	Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments (PR Newswire)
Feb-18-26 09:30PM	RBC Capital Cite GH Research PLC's (GHRS) Long-Term Sales Potential Following Psychedelics Symposium (Insider Monkey)
04:25AM	Psychedelics stocks rise as Compass psilocybin drug heads to FDA (BioPharma Dive)
10:00AM	Loading…
Jan-05-26 10:00AM	Stocks Climb on AI Spending Optimism and Strength in Energy Producers (Barchart) +16.77%
09:23AM	Psychedelics-Tied GH Skyrockets On FDA Go-Ahead For Depression Drug (Investor's Business Daily)
09:01AM	A small company can now advance its psychedelic into Phase 3. Here's why that matters to other psychedelic biotechs. (MarketWatch)
07:00AM	GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026 (GlobeNewswire)
Jan-02-26 04:01PM	GH Research to Announce IND Status for GH001 (GlobeNewswire)
Nov-10-25 09:55AM	Wall Street Analysts Think GH Research (GHRS) Could Surge 130.59%: Read This Before Placing a Bet (Zacks)
Nov-06-25 07:00AM	GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-13-25 09:30AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-09-25 07:00AM	GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress (GlobeNewswire)
Sep-02-25 03:52AM	GH Research PLC (GHRS) Reports 73% Remission in Phase 2b Depression Trial (Insider Monkey)
Aug-07-25 07:00AM	GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-31-25 12:58PM	In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A (BioPharma Dive)
Jul-28-25 10:04AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-23-25 08:00AM	GH Research Announces Global Pivotal Program Plans and Further Development Updates (GlobeNewswire) -14.68%
Jul-16-25 09:55AM	Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade (Zacks) +8.13%
Jul-09-25 07:20AM	GH Research Responds to FDA Clinical Hold on Depression Treatment GH001 Ahead of Schedule (Insider Monkey) +6.98%
Jun-23-25 09:51AM	Compasss Psychedelic Drug to Treat Depression Meets Goal in Trial (Bloomberg) -5.12%
Jun-20-25 01:00PM	GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule (GlobeNewswire)
Jun-19-25 10:10AM	Trump Trade: President said to weigh possible U.S. strike against Iran (TipRanks)
09:26AM	Psychedelic advocates hopeful Trump administration will support space, STAT says (TipRanks)
May-15-25 07:00AM	GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting (GlobeNewswire) +7.21%
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks)
May-08-25 07:00AM	GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +5.16%
May-05-25 12:00PM	What Makes GH Research (GHRS) a New Buy Stock (Zacks)
Mar-22-25 10:30AM	Psychedelic: Exclusive talk with biotech company Clearmind Medicine (TipRanks)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks)
Mar-14-25 11:40AM	Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial (TipRanks)
Mar-13-25 05:30PM	Guggenheim starts GH Research at Buy, sees long-term upside potential (TipRanks)
Mar-03-25 11:06AM	Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025 (Insider Monkey) -9.08%
Mar-01-25 11:00AM	GH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025 (Insider Monkey)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
Feb-27-25 07:00AM	GH Research Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-24-25 01:49PM	GH Research PLC (GHRS): Among the Best Performing Small Cap Stocks So Far In 2025 (Insider Monkey)
Feb-04-25 08:52PM	GH Research Announces Pricing of $150 Million Public Offering (GlobeNewswire) -9.31% -8.06%
Feb-03-25 08:22PM	Why GH Research PLC (GHRS) Is Skyrocketing So Far In 2025 (Insider Monkey) +69.72%
04:03PM	GH Research Announces Proposed Public Offering (GlobeNewswire)
07:07AM	Shares of psychedelics biotech nearly double on depression data (BioPharma Dive)
07:00AM	GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction (GlobeNewswire)
Jan-31-25 04:01PM	GH Research to Provide Update on Phase 2b Trial with GH001 in TRD (GlobeNewswire) +9.39%
Jan-10-25 07:00AM	GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents (GlobeNewswire)
Nov-20-24 09:55AM	Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect? (Zacks) +13.94%
Nov-18-24 07:19AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Nov-14-24 07:00AM	GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Sep-09-24 12:00PM	GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade (Zacks)
09:35AM	After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS) (Zacks)
Sep-08-24 09:14PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-03-24 07:05AM	GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.57%
07:00AM	GH Research Announces Appointment of Dr. Velichka "Villy" Valcheva to Chief Executive Officer (GlobeNewswire)
Jul-06-24 07:21AM	3 Psychedelic Stocks to Ride to the Moon and Beyond (InvestorPlace)
Jul-03-24 09:48AM	Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns (InvestorPlace)
May-13-24 08:50AM	Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why (Zacks)
May-10-24 09:55AM	Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know (Zacks) +6.84%
May-03-24 01:53PM	GHRS Stock Earnings: GH Research Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-24 09:55AM	How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28% (Zacks)
Feb-29-24 07:00AM	GH Research Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire) +7.90%
Jan-18-24 04:30PM	GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression (GlobeNewswire)
Jan-16-24 09:55AM	Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-29-23 08:47AM	11 Best Psychedelic Stocks to Buy in 2024 (Insider Monkey)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey) -7.32%
Dec-19-23 11:07AM	15 Best Falling Stocks To Buy Now (Insider Monkey) +9.13%
Nov-09-23 04:45PM	GH Research Reports Third Quarter Financial Results and Provides Business Updates (GlobeNewswire)
Sep-29-23 04:45PM	GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression (GlobeNewswire)
Aug-23-23 07:00AM	GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-17-23 11:53AM	Here's Why We're Not Too Worried About GH Research's (NASDAQ:GHRS) Cash Burn Situation (Simply Wall St.)
Jul-06-23 09:40AM	Its Really a Brain Chemistry Issue: Elon Musk Embraces Ketamine in the Battle Against Depression Here Are 2 Psychedelic Stocks That Analysts Like (TipRanks)
Jun-29-23 08:00AM	The 3 Best Psychedelic Stocks to Buy Now (InvestorPlace)
May-11-23 07:30AM	GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-23-23 01:56PM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks) +14.78%
Mar-12-23 12:22PM	10 Best Psychedelic Stocks to Buy According to Hedge Funds (Insider Monkey)

Show Previous News

GH Research Plc is a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients with psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schonharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

Co-Founder & Non-Executive Chairman of the BoardMr. Florian Schonharting M.Sc. (Econ)

M.Sc.Dr. Velichka Valcheva M.D.

Co-Founder & MD of IrelandMr. Magnus Halle

Vice President of FinanceMs. Julie Ryan F.C.A.

Chief Operating OfficerMr. Aaron Cameron M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GHRS

GH Research PLC

Upgrade your Finviz experience